Search Results

Filter
  • 1-10 of  37,226 results for ""RITUXIMAB""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab.

  • Authors : Gordilho JO; Department of Dermatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.; Miyamoto D

Subjects: Epidermolysis Bullosa* ; Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/diagnosis ; Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/drug therapy

  • Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jan; Vol. 38 (1), pp. e45-e47. Date of Electronic Publication: 2023 Aug Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease.

Subjects: Rituximab*/Rituximab*/Rituximab*/adverse effects; Humans ; Retrospective Studies

  • Source: RMD open [RMD Open] 2024 Jan 30; Vol. 10 (1). Date of Electronic Publication: 2024 Jan 30.Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101662038 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

High-Dose ERT, Rituximab, and Early HSCT in an Infant with Wolman's Disease.

  • Authors : Eskandari SK; From the Department of Metabolic Diseases, Beatrix Children's Hospital (S.K.E., F.B., F.J.S., C.M.A.L.), and the Department of Surgery (S.K.E.), University Medical Center (UMC) Groningen, Groningen, the Division of Pediatrics (E.G.M.R., M.B., P.M.H., C.A.L.) and the Department of Metabolic Diseases (P.M.H.), UMC Utrecht, and the Department of Stem Cell Transplantation, Princess Máxima Center for Pediatric Oncology (E.G.M.R., M.B., C.A.L.), Utrecht, and the Department of Pediatrics, Gelre Hospital, Apeldoorn (D.J.P.) - all in the Netherlands.; Revenich EGM

Subjects: Dietary Fats*/Dietary Fats*/Dietary Fats*/adverse effects ; Enzyme Replacement Therapy*/Enzyme Replacement Therapy*/Enzyme Replacement Therapy*/methods ; Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/methods

  • Source: The New England journal of medicine [N Engl J Med] 2024 Feb 15; Vol. 390 (7), pp. 623-629.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

  • Authors : Ip A; Division of Oncology, Hackensack University Medical Center, Hackensack, NJ, USA.; Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ, USA.

Subjects: Lenalidomide*/Lenalidomide*/Lenalidomide*/administration & dosage ; Lenalidomide*/Lenalidomide*/Lenalidomide*/adverse effects ; Lymphoma, Mantle-Cell*/Lymphoma, Mantle-Cell*/Lymphoma, Mantle-Cell*/drug therapy

  • Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (14), pp. 2225-2235. Date of Electronic Publication: 2023 Dec 25.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

  • Authors : Lim KJC; St Vincent's Hospital Melbourne, Melbourne, VIC, 3065 Australia. Electronic address: .; Filshie R

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Burkitt Lymphoma*/Burkitt Lymphoma*/Burkitt Lymphoma*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy EPOCH protocol

  • Source: The Lancet. Haematology [Lancet Haematol] 2023 Dec; Vol. 10 (12), pp. e942-e943. Date of Electronic Publication: 2023 Oct 31.Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.

  • Authors : Chen P; Department of Nephrology, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, China.; Shanxi Genetic Engineering Center for Experimental Animal Models, Taiyuan, China.

Subjects: Glomerulonephritis, Membranous*/Glomerulonephritis, Membranous*/Glomerulonephritis, Membranous*/drug therapy ; Rituximab*/Rituximab*/Rituximab*/adverse effects ; Rituximab*/Rituximab*/Rituximab*/therapeutic use

  • Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Feb 15; Vol. 14, pp. 1044782. Date of Electronic Publication: 2023 Feb 15 (Print Publication: 2023).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print

Record details

×
Academic Journal

Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.

  • Authors : Liu L; Department of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.; Lu H

Subjects: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*/Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*/Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*/diagnosis ; Antibodies, Antineutrophil Cytoplasmic* ; Rituximab*/Rituximab*/Rituximab*/adverse effects

  • Source: BMC nephrology [BMC Nephrol] 2023 Feb 08; Vol. 24 (1), pp. 28. Date of Electronic Publication: 2023 Feb 08.Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369

Record details

×
Academic Journal

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis.

  • Authors : Schirmer JH; Clinic for Internal Medicine I, Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany .; Sanchez-Alamo B

Subjects: Granulomatosis with Polyangiitis* ; Microscopic Polyangiitis* ; Cyclophosphamide*/Cyclophosphamide*/Cyclophosphamide*/therapeutic use

  • Source: RMD open [RMD Open] 2023 Jul; Vol. 9 (3).Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101662038 Publication Model: Print Cited Medium: Internet ISSN: 2056-5933

Record details

×
Academic Journal

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.

Subjects: Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/drug therapy ; Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/genetics ; Receptors, IgG*/Receptors, IgG*/Receptors, IgG*/drug effects

  • Source: EBioMedicine [EBioMedicine] 2022 Dec; Vol. 86, pp. 104343. Date of Electronic Publication: 2022 Nov 11.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.

  • Authors : Barreras P; From the Department of Neurology (P.B., E.S.V., A.G.F., K.C.F., C.A.P., S.D.N., E.M.M.C.R., P.A.C., E.S.S.), Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Neurology (M.L.), Harvard University, Boston, MA.

Subjects: Agammaglobulinemia*/Agammaglobulinemia*/Agammaglobulinemia*/etiology ; Neuromyelitis Optica*/Neuromyelitis Optica*/Neuromyelitis Optica*/complications ; Neuromyelitis Optica*/Neuromyelitis Optica*/Neuromyelitis Optica*/drug therapy

  • Source: Neurology [Neurology] 2022 Nov 29; Vol. 99 (22), pp. e2504-e2516. Date of Electronic Publication: 2022 Aug 31.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium:

Record details

×
  • 1-10 of  37,226 results for ""RITUXIMAB""